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Abstract
Hypercoagulability observed in patients with inflam-
matory bowel diseases (IBD) may lead to thromboem-
bolic events (TE), which affect the venous and arterial 
systems alike and are an important factor in patients’ 
morbidity and mortality. The risk of TE in IBD patients 
has been demonstrated to be approximately three-
fold higher as compared to the general population. The 
pathogenesis of thrombosis in IBD patients is multifac-
torial and not fully explained. The most commonly list-
ed factors include genetic and immune abnormalities, 
disequilibrium between procoagulant and anticoagulant 
factors, although recently, the role of endothelial dam-
age as an IBD-triggering factor is underlined. Several 
studies report that the levels of some coagulation en-
zymes, including fibrinogen, factors Ⅴ, Ⅶ, Ⅷ, active 
factor Ⅺ, tissue factor, prothrombin fragment 1 + 2 
and the thrombin-antithrombin complex, are altered in 
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IBD patients. It has been demonstrated that there is 
a significant decrease of tissue plasminogen activator 
level, a marked increase of plasminogen activator in-
hibitor type 1 and thrombin-activable fibrinolysis inhibi-
tor, a significantly lower level of antithrombin Ⅲ and 
tissue factor pathway inhibitor. IBD patients have been 
also observed to produce an increased amount of vari-
ous anticoagulant antibodies. Hyperhomocysteinemia, 
which is a potential risk factor for TE was also observed 
in some IBD patients. Further studies are necessary to 
assess the role of coagulation abnormalities in IBD eti-
ology and to determine indications for thromboprophy-
lactic treatment in patients at high risk of developing 
TE.
© 2014 Baishideng Publishing Group Co., Limited. All rights 
reserved.
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Core tip: Thromboembolic events (TE) in inflammatory 
bowel diseases (IBD) patients are often overlooked. 
They affect both the venous and arterial systems. The 
inflammatory process initiates clotting, impairs the fi-
brinolytic system and decreases the activity of natural 
anticoagulation mechanisms. Depression of anticoagu-
lation mechanisms not only increases thrombosis, but 
also potentiates the inflammatory process. The objec-
tive of the present report is to demonstrate the high 
significance of a problem posed by hypercoagulability in 
IBD patients based on TE epidemiology, and to present 
abnormalities in the hemostatic system.
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INTRODUCTION
Inflammatory bowel diseases which include Crohn’s disease 
(CD) and ulcerative colitis (UC), are systemic disorders 
that predominantly affect the gastrointestinal tract, but 
are also associated with a number of  extraintestestinal 
manifestations. The majority of  extraintestinal complica-
tions are characterized by less intense symptoms as com-
pared to those associated with the primary disease, but 
thromboembolic events (TE) may increase mortality rates 
in inflammatory bowel diseases (IBD)[1-3]. TE in IBD are 
often overlooked, since their detection rate in IBD pa-
tients is only 6% as compared amounts approximately to 
40 % in postmortem examinations[4-6].
The pathogenesis of  thrombosis in IBD patients is 
multifactorial and not fully explained. Numerous inves-
tigations have demonstrated qualitative and quantitative 
abnormalities in procoagulation, anticoagulation and fi-
brinolytic factors that predispose to thrombosis develop-
ment in IBD, although some authors have not found any 
risk factors in about one-half  of  IBD patients diagnosed 
with thrombosis. 
IBD is a result of  an interaction of  acquired and ge-
netic factors, with the very inflammatory process being 
of  high significance as well[1,2]. The inflammatory pro-
cess initiates clotting, impairs the fibrinolytic system and 
decreases the activity of  natural anticoagulation mecha-
nisms; on the other hand, natural anticoagulation factors 
reduce elevated levels of  cytokines triggered by inflam-
mation[7]. Thus, depression of  anticoagulation mecha-
nisms not only increases thrombosis, but also potentiates 
the inflammatory process. An example of  the effect of  
procoagulation factors on the inflammatory process may 
be found in thrombin, which increases the production of  
tumor necrosis factor, interleukin (IL)-6 and IL-10 by sig-
naling protease-activated receptors and, therefore, is able 
to amplify and modify inflammation[8].
The objective of  the present report is to demonstrate 
the high significance of  a problem posed by hypercoagu-
lability in IBD patients based on TE epidemiology, and 
to present abnormalities in the hemostatic system.
EpIDEmIOlOgy Of TE IN IBD paTIENTs
TE are among complications demonstrated in IBD pa-
tients, which affect the venous and arterial systems alike 
and are an important factor in patients’ morbidity and 
mortality. The risk of  systemic TE development in IBD 
patients has been demonstrated to be approximately 
three-fold higher as compared to the general popula-
tion[1,2]. TE in IBD has been also demonstrated to de-
velop in younger individuals as compared to the general 
population[9].
The incidence of  TE in IBD has been estimated to be 
approximatively 0.1%-0.5% per year, with an overall mor-
tality rate as high as 25% per episode[2]. In clinical studies, 
the incidence rate of  TE in IBD patients is estimated as 
falling in the range of  1.3%-7.7%[1,4,5], although the rate 
increases to 39%-41% in postmortem examinations[1,6]. 
For this reason, based on clinical studies published to 
date, one may say that systemic TE in patients with CD 
and UC are underdiagnosed.
TE occur mainly during disease exacerbation and are 
more common in IBD patients with markedly elevated 
inflammatory markers and presenting with other compli-
cations, such as strictures, fistulisation, or abscesses[1,5,10]. 
The incidence of  such episodes is also correlated with 
the extent of  the disease, especially in pancolonic UC pa-
tients and in CD patients with colonic involvement[11,12]. 
However, proctocolectomy is not protective of  recurrent 
deep venous thrombosis (DVT) or pulmonary embolism 
(PE)[11]. While studying the frequency of  TE recurrence 
in IBD patients in several-year follow-up, an increased 
risk of  venous thromboembolism (VTE) was demon-
strated as compared to patients without IBD[1,11,13]. In ad-
dition, the risk is three times higher in males as compared 
to females[13]. In the majority of  women, pregnancy is 
uncomplicated[14]. No higher risk of  TE was observed in 
pregnant women[15].
The age at first VTE is significantly associated with 
an increased risk of  recurrence[13]. The study assessing 
the risk of  TE in the population of  Danish children with 
IBD showed that relative risks were higher in patients 
under 20 years of  age, though actual incidence increased 
with age[16]. A higher incidence of  cerebral TE in pediat-
ric population with IBD was noticed, as well[17].
When compared to general outpatient population, the 
risk of  VTE is 16 times higher in IBD patients who are 
not hospitalized during the active phase of  the disease[18]. 
However, it is important that thrombosis is also reported 
in patients with well-controlled disease[5,18]. It has been 
suggested that in contrast to CD, UC is associated with 
an increased risk of  TE in patients with low-activity dis-
ease or even during remission[19,20].
The most common TE in IBD are lower extremity 
DVT and PE[21]. Occasionally, VTE occur in the cerebral, 
hepatic, portal, retinal, and mesenteric veins[21-23]. Arterial 
TE occur less frequently than VTE; the former include 
thrombosis of  the cerebral and retinal arteries and also 
arteries of  upper and lower limbs[23-25]. Moreover, there 
have been reports of  cases of  coronary artery thrombo-
sis in young patients with IBD[26].
It is important to remember that in IBD, thrombosis 
involves not only the systemic veins and arteries, micro-
thrombi may involve the vasculature of  the uninflammed 
intestine as well[27]. For instance, in patients with CD 
platelet thrombi cross-linked with fibrin were demon-
strated in the mucosal microvasculature[28], in patients 
with UC intracapillary clots have been observed in rectal 
biopsies[29]. Several observational studies have shown a 
potential benefit of  using heparin treatment in patients 
with IBD[30,31].
Very interesting results have been presented by 
Thompson et al[32]. The authors have observed that in 
patients with inherited bleeding disorders such as hemo-
philia A, hemophilia B and von Willebrand disease, the 
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risk of  development of  either CD or UC was significant-
ly decreased.
It has been suggested that hypercoagulability, pro-
thrombotic state and vascular occlusion play an impor-
tant role in the pathogenesis of  IBD.
ETIOlOgy Of ThROmBOsIs IN IBD
IBD patients demonstrate disequilibrium between pro-
coagulant and anticoagulant factors, which predisposes 
them to develop thrombosis; the abnormalities are both 
quantitative and qualitative[33].
Acquired factors that affect disturbances in the 
hemostatic system in IBD include prolonged immobi-
lization, surgical procedures, central venous catheters, 
glucocorticosteroids therapy, oral contraceptives, hor-
monal replacement therapy, cigarette smoking, hyperho-
mocysteinemia, vitamin deficiency, dehydration, as well 
as damage to the vascular endothelium[21,34,35] (Table 1). 
Hypercoagulability in both CD and UC may be also trig-
gered by genetic factors[20].
The hemostatic system is an indispensable element 
of  each inflammatory process. During the inflammatory 
process, not only proteases originating from inflamma-
tory cells are activated, but also those originating from 
the coagulation and fibrinolysis system[1,36]. For this rea-
son, an increased risk of  TE complications is also pres-
ent during remission period - mostly in patients with UC. 
The phenomenon is most likely related to the interaction 
between cytokine mediators of  chronic inflammation and 
the coagulation cascade[34].
The mechanism of  an increased thromboembolic 
risk in IBD is complex, multifactorial and not fully un-
derstood. It appears to be multifactorial because no con-
sistent unifying etiology has been identified. However, 
there are also studies available, where in approximately 
one-half  of  IBD patients who developed TE no possible 
causative factors associated with the complications have 
been identified[37].
Coagulation cascade
The coagulation cascade is essentially a series of  enzy-
matic conversions, turning inactive proenzymes into 
activated enzymes and culminating in the formation of  
thrombin. Thrombin then converts the soluble plasma 
protein - fibrinogen - precursor into the insoluble fibrous 
protein - fibrin. Each reaction in the pathway results from 
the assembly of  a complex composed of  an enzyme (an 
activated coagulation factor), a substrate (a proenzyme 
form of  a coagulation factor) and a cofactor (a reaction 
accelerator).
In the classical cascade model, coagulation has been 
divided into the extrinsic and intrinsic pathway, converging 
at the point where factor Ⅹ (FⅩ) is activated (Figure 1). 
Several studies report that the levels of  some co-
agulation enzymes are altered in IBD patients, including 
increased fibrinogen, increased factor Ⅴ (FⅤ), Ⅶ (FⅦ) 
and Ⅷ (FⅧ) and also increased prothrombin fragment 1 
+ 2 and the thrombin-antithrombin complex[21,34]. The in-
crease in the level of  these coagulation factors in CD and 
UC patients is associated with disease activity[34,38]. Elevat-
ed levels of  circulating active factor Ⅺ (FⅪ) and tissue 
factor (TF) have been also reported in IBD[39]. Another 
abnormality in the coagulation cascade in IBD patients 
is a decrease in the level of  factor XIII (FXIII)[34,40-44]. In 
the majority of  publications a decrease of  FXIII level 
was described in patients with active phase of  CD and 
UC in comparison to non-active phase[34,41,42,44]. There is 
also a research that does not demonstrate any correla-
tion between disease activity and a FXIII level[40]. One of  
the potential causes of  reduced activated FXIII plasma 
levels in IBD might be its consumption in the repair of  
injured tissue[40,41,43] or in the increased formation of  mi-
crothrombi[42]. 
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Figure 1  Coagulation cascade model. ↑/↓: Changes in coagulation factors, in patients with inflammatory bowel diseases.
Table 1  Acquired prothrombotic factors in inflammatory 
bowel diseases
Dehydration
Glucocorticosteroids therapy
Prolonged immobilization
Central venous catheters
Surgical procedures
Oral contraceptives/hormonal replacement therapy
Smoking
Hyperhomocysteinemia
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presses plasminogen activation, thereby attenuating fi-
brinolysis. In addition to suppressing fibrinolysis, TAFIa 
may also be involved in inflammation. Its potential role 
as a natural anti-inflammatory molecule is currently be-
ing explored, with recognition of  its ability to inactivate 
potent anaphylatoxins, C3a and C5a, as well as the proin-
flammatory mediators, bradykinin and osteopontin[45,46]. 
TAFI has been also demonstrated to be associated not 
only with development of  thromboembolic complica-
tions in various disease entities, but also to affect the 
course of  such diseases[46]. In IBD, a significant correla-
tion has been demonstrated between TAFIa and such in-
flammatory markers as CRP, fibrinogen, platelets, as well 
as disease activity[46].
Plasma coagulation inhibitors 
Figure 3 presents plasma coagulation inhibitors.
Antithrombin Ⅲ (ATⅢ) is the best known natural 
coagulation inhibitor, its activation is triggered by hepa-
rin secreted by mast cells or administered exogenously. 
ATIII is predominantly synthesized in the liver, vascular 
endothelial cells, megakaryocytes and platelets. It is the 
most important endogenous thrombin inhibitor; it forms 
complex with thrombin in a 1:1 molar ratio, which is sub-
sequently removed from blood by macrophages. ATⅢ 
also inactivates factor Ⅹa, factor Ⅻa, factor Ⅺa and fac-
tor Ⅸa. In addition to anticoagulation properties, ATⅢ 
has been demonstrated to have anti-inflammatory prop-
erties[32]. ATⅢ decreases expression of  CD11b/CD18 
cell surface receptors on leukocytes, which decreases 
leukocyte adhesion, decreases expression of  tissue factor 
and IL-6 in monocytes and endothelium. ATⅢ also in-
creases prostacyclin formation and decreases nuclear fac-
tor (NFκB)[36]. IBD patients have been demonstrated to 
have a significantly lower levels of  ATⅢ and TF pathway 
inhibitor (TFPI) as compared to the controls[8,21,34]. 
TFPI is a protein produced by vascular endothelial 
cells and megakaryocytes. It is a Kunitz-type protein with 
three inhibitor domains: the first domain inhibits the fac-
tor Ⅶa/tissue factor complex, the second binds active 
factor Ⅹ, the third is responsible for binding TFPI with 
heparin and lipoproteins[36]. TFPI is a total inhibitor of  
the TF-dependent coagulation cascade and a marker of  
endothelial damage[36]. 
Changes in coagulation and fibrynolytic systems are 
presented in Table 2. 
PC system 
The PC system is the most important element of  antico-
agulation mechanisms. It is presented in Figure 4.
The PC pathway is activated by thrombin bound to 
endothelial thrombomodulin (TM). Following binding 
with TM, thrombin acquires abilities to activate PC. PC 
activation is facilitated when PC is bound to the endothe-
lial cell PC receptor (EPCR). In turn, APC in the pres-
ence of  protein S (PS) cofactor inactivates active FⅧ and 
FⅤ[7,36]. Additionally, APC has profibrinolytic properties, 
since it binds PAI-1[7,36]. 
Anticoagulation mechanisms 
Anticoagulation mechanisms, often referred to by a sim-
plified term “anticoagulation system” are responsible for 
balancing the procoagulation tendency in the hemostatic 
system. The system includes the fibrinolysis system, plas-
ma coagulation inhibitors, protein C (PC) anticoagulant 
system and vascular wall.
Fibrinolysis system 
The basic element of  the fibrinolysis system is plasmino-
gen, which - following its transformation by activators to 
an active substance, i.e., plasmin, acts upon fibrinogen, fi-
brin, FⅤ, FⅦ, FXIII, von Willebrand factor and platelet 
glycoproteins.
The elements of  the fibrinolysis system - both activa-
tors and inhibitors - are presented in Figure 2.
Disturbances in the fibrinolysis system are another 
very important factor in IBD patients that is associated 
with hypercoagulability. The fibrynolytic system has been 
widely investigated in patients with CD and UC, and hy-
pofibrinolysis has been described as a potential contribu-
tor to the hypercoagulable state in IBD patients[21,34]. 
In IBD patients, there has been demonstrated a sig-
nificant decrease of  tissue plasminogen activator (tPA) 
level, the principal activator of  the fibrinolysis system, as 
compared with the controls[34,45]. With respect to inhibi-
tors of  the fibrinolysis system, IBD has been shown to 
demonstrate a marked increase of  plasminogen activator 
inhibitor 1 (PAI-1) and thrombin-activatable fibrinolysis 
inhibitor (TAFI) levels as compared to the healthy con-
trol subjects[45,46].
TAFI is a modulator of  homeostasis that provides 
a link between the coagulation system and fibrinolysis 
system, as well as between the hemostatic system and the 
inflammatory process[46].
TAFI, a plasma zymogen, can be activated by throm-
bin, the thrombin-thrombomodulin complex, or plasmin. 
The activated form of  TAFI (TAFIa) removes C-terminal 
lysine residues from plasmin-modified fibrin which sup-
Plasminogen
Plasmin
Fibrin
(↓) tPA
uPA 
PAI-1 (↑)
PAI-2 
Α2-Antiplasmin
TAFI (↑)
FDP, FgDP
+
+
-
-
-
-
Figure 2  The elements of the fibrinolytic system. tPA: Tissue-type plas-
minogen activator; uPA: Urokinase plasminogen activator; PAI-1: Plasminogen 
activator inhibitor type 1; TAFI: Thrombin activatable fibrinolysis inhibitor; FDP: 
Fibrin degradation products; FgDP: Fibrinogen degradation products. ↑/↓: 
Changes in coagulation factors, in patients with inflammatory bowel diseases.
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Studies have demonstrated that TM as well as APC, 
in addition to exhibiting anticoagulation properties, also 
affect the course of  the inflammatory process, apoptosis 
and endothelial barrier[36,47]. Reports of  studies on PC, PS 
and TM levels in patients with CD and UC are contradic-
tory[18,48], although some investigators have demonstrated 
PC and/or PS deficiency during active IBD phase[21,34]. 
The available reports regarding plasma TM concen-
trations in IBD patients have also yielded conflicting 
results. Several studies have demonstrated that higher 
TM concentrations occur only in active CD patients as 
compared to the controls; the above authors have failed 
to demonstrate any changes in PC and PS levels in IBD. 
In another study, TM concentrations were higher in UC 
than in the healthy controls[47].
The controversial character of  these findings may re-
sult from differences in IBD populations studied (demo-
graphic and clinical features, definition of  disease activity 
and evaluation)[47].
It may be also suggested that increased TM or PC 
levels described by some authors may be associated with 
their anti-inflammatory properties[47].
Further studies assessing anti-inflammatory proper-
ties of  TM and PC in IBD are necessary. 
Vascular wall 
Of  importance in regulation of  hemostatic mechanisms 
are subsequent layers of  vascular wall: smooth muscles 
- vasospasm, subendothelial layer - activation of  the he-
mostatic system following endothelial damage, platelet 
activation, and endothelium.
Hemostatic activity of  the endothelium under physi-
ological conditions consists of  ensuring non-clotting of  
blood, non-thrombogenicity of  vascular surface, and 
- after endothelial damage - limiting the thrombus to 
the thrombogenic site. Endothelial damage disturbs the 
multifactorial equilibrium provided by endothelial cells, 
causing development of  numerous significant pathologi-
cal sequelae, such as thrombi formation, hypertension, 
atherosclerotic lesions, disturbances in tissue perfusion, 
angiogenesis and inflammatory infiltration[49]. 
Endothelial damage occurring in numerous diseases 
is evident though increasing levels of  endothelial injury 
markers. The most frequently used biochemical mark-
ers of  endothelial damage include von Willebrand factor 
(vWF), TM, vascular cell adhesion molecule 1 (VCAM-1), 
intercellular adhesion molecule 1 (ICAM-1) and endothe-
lin-1 (ET-1).
In recent years, asymmetric dimethylarginine (ADMA) 
has been also classified as an endothelial damage marker. 
It is synthesized during the methylation of  protein argi-
nine residues by protein arginine methyltransferases and 
released during proteolysis. ADMA is a major endog-
enous NO synthase inhibitor and a competitive inhibitor 
of  the cellular L-arginine uptake[50]. Elevation of  ADMA 
induces dysfunction of  the endothelium, which becomes 
clinically evident by impaired endothelium-dependent va-
sodilation, hyperaggregability of  platelets and enhanced 
monocyte adhesion[50].
↓ AT Ⅲ  
Ⅻa
Ⅺa
Ⅸa
Ⅹa
Ⅱa
TF-Ⅻa
-
-
-
-
-
-
+
+
TF-Ⅶa
Ⅹa
Ⅷa
Ⅴa
TFPI  ↓
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-
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-
Figure 3  Plasma coagulation inhibitors. AT Ⅲ: Antithrombin Ⅲ; TF: Tissue factor; TFPI: TF pathway inhibitor; PS: Protein S; APC: Activated protein C. ↓: Changes 
in plasma coagulation inhibitors, in patients with inflammatory bowel diseases.
Table 2  Changes in coagulation and fibrinolytic systems in 
patients with in inflammatory bowel diseases
Coagulation factors Fibrinolytic factors Plasma coagulation 
inhibitors
Fibrynogen ↑ TAFI ↑ Antithrombin Ⅲ ↓
Factor Ⅴ ↑ PAI-1 ↑ TFPI ↓
Factor Ⅶ ↑ tPA  ↓
Factor Ⅷ ↑
Factor Ⅺ ↑
Prothrombin fragment 
1 + 2 ↑
Thrombin-antithrom-
bin complex ↑
TF ↑
FXIII ↓
tPA: Tissue plasminogen activator; TAFI: Thrombin-activatable fibrinoly-
sis inhibitor; PAI-1: Plasminogen activator inhibitor 1; TFPI: Tissue factor 
pathway inhibitor.
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According to the published studies, there has been ob-
served an increase of  such endothelial damage markers as 
vWF, TM, endothelial PC receptor (EPCR) and ADMA in 
IBD patients; they have been also found to correlate with 
disease activity and inflammatory markers[34,46,47,50].
Vascular endothelial damage is believed to be a factor 
that increases the risk of  TE in IBD. 
Homocysteine 
Homocysteine is an amino acid formed from S-adenosylo-
methionine (SAM), in all types of  cells in the human body. 
It participates in metabolism of  numerous compounds 
that are indispensable for the organism to function.
Homocysteine is a pro-coagulation factor, since it 
evokes changes in vascular walls and triggers increased 
expression of  TF and FⅤ, decreased expression of  TM 
and tPA and decreased activation of  PC. Elevated plasma 
homocysteine levels facilitate development of  both arte-
rial and venous thrombosis[34]. Recently, homocysteine 
has been also shown to participate in microvascular in-
flammation in IBD, triggering endothelial inflammation, 
resulting in VCAM-1 upregulation, monocyte chemoat-
tractant protein-1 (MCP-1) production and p38 phos-
phorylation. Such changes lead to increased adhesion of  
T cells and monocytes to the endothelium[51].
Hyperhomocysteinemia is a potential risk factor for 
TE in IBD patients and can be secondary to folic acid 
and vitamin B12 deficiencies, medications (methotrexate, 
sulphalazine, glucocorticosteroids), smoking and nutri-
tional deficiencies[21,34].
Both plasma and mucosal homocysteine levels have 
been demonstrated to be significantly higher in IBD pa-
tients as compared to the healthy controls and correlated 
with disease activity[51,52]. However, there is no evidence 
that an increase in homocysteine level is of  greater pro-
portion in IBD patients with TE vs those without. The 
risk assessment of  hyperhomocysteinemia-related throm-
bosis in IBD requires further investigation[52].
Platelets in IBD
Blood platelet levels may be considerably increased in 
active IBD both in CD and UC patients; this is a reac-
tion to an intensified inflammatory process. Regardless 
of  inflammatory process exacerbation, approximately 
30%-50% of  IBD patients develop spontaneous platelet 
aggregation or platelet hypersensitivity to low concentra-
tions of  aggregating agents[53]. The final stage of  plate-
let hyperactivation has been found to be mediated by 
the CD40-CD40 ligand (CD40L) pathway. The surface 
CD40L is an activation marker that allows platelets to in-
teract with a broad variety of  immune and non-immune 
cells. It has been demonstrated that in IBD patients 
platelets overexpress CD40L protein up to four times 
more frequently than platelets from control subjects, and 
release more soluble CD40L (sCD40L) to the plasma, 
leading to a 15 fold increase in CD40L plasma levels. In 
general elevated levels of  sCD40L are associated with 
an increased risk of  TE development which is also true 
for patients with IBD[53]. It has been observed that an 
increased platelet activity in IBD is also dependent on 
increased expression of  surface activation markers, such 
as P-selectin and GP53 and on serum levels of  platelet 
activation marker β-thromboglobulin[34,54]. The higher 
platelet activity state mentioned above has been noted 
to be independent of  clinical activity of  the disease; the 
chronic disease process has been suggested to lead to in-
creased platelet activity even in remission state[34,54].
Finally, platelets are involved in chronic intestinal 
inflammation, what has been demonstrated in studies 
evaluating anus sections collected from IBD patients. 
Mucosal intravascular microthrombi have been shown 
both in CD and UC patients[29,53]. In addition, the inves-
tigators have found that platelets of  patients with IBD 
express high levels of  surface CD40L, creating a physical 
and biological bridge that allows interaction with human 
intestinal microvascular endothelial cells causing their 
activation[34,54], what leads to up-regulation of  VCAM-1 
and ICAM-1 by activated platelets through the CD40-
dependent pathway and to increased production of  IL-8 
by endothelial cells, also through this pathway, and an 
increase in T cell adhesion to the endothelium[34].
Autoantibodies
IBD patients have been observed to produce increased 
amounts of  various antibodies; some of  them are anti-
coagulant antibodies and thus may increase the risk of  
thrombosis.
Antiphospholipid antibodies include anticardiolipin 
(aCL) antibodies and lupus anticoagulants (LAC). The an-
tibodies may increase the risk of  thrombosis through ac-
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Figure 4  Protein C system. PC: Protein C; APC: Activated protein C; S: 
Protein S; TM: Thrombomodulin; PAT-1: Plasminogen activator inhibitor 1; 
EPCR: Endothelial cell PC receptor; C4bBP: C4b-binding protein; Ⅴa: Ⅴ 
active; Ⅴi: Ⅴ inactive; Ⅷa: Ⅷ active; VIIIi: VIII inactive. ↑/↓: Changes in 
protein C system, in patients with inflammatory bowel diseases.
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tivation of  platelets and endothelial cells and by decreas-
ing anticoagulant activity of  proteins. In IBD patients as 
compared to the controls, the level of  aCL antibodies is 
approximately 20%-30% higher, while the level of  LAC 
antibodies is approximately 19% higher[55,56].
In IBD, the prevalence of  antibodies against β2-
glucoprotein Ⅰ (β2-GPI), the cofactor that mediates 
binding of  aCL antibodies to cardiolipin, is higher than 
in the controls, with an average incidence of  9%[56].
Antibodies against PS have been described in patients 
with IBD. The antibodies could reduce the natural antico-
agulant potential[48]. However, in up-to-date publications 
there is no good evidence that these antibodies play any 
role in thrombotic risk[48].
Nevertheless, no significant differences have been 
demonstrated in the prevalence of  the above antibod-
ies in IBD patients with diagnosed TE as opposed to 
the IBD group without such complications[48,56]. Further 
observations and studies are necessary to allow for a pos-
sible confirmation of  the role of  these antibodies in the 
development of  TE.
Genetic factors
Genetic factors that have been implicated to play role 
in TE in IBD include FⅤ Leiden (FVL, G1691A), the 
genetic variation of  the prothrombin gene mutation 
(G20210A), methylenetetrahydrofolate reductase gene 
mutation (MTHFR, C677T), plasminogen activator 
inhibitor type 1 (PAI-1) gene mutation and FXIII (val-
34leu)[20,34,57-59].
FVL is an arginine to glutamine missense mutation in 
the FV gene at position 506. FVL is the most frequent 
cause of  inherited thrombophilia, it renders the activated 
FV form relatively resistant to degradation by activated 
protein C (APC), resulting in higher thrombin genera-
tion. The prevalence of  FVL ranges from 20% to 30% 
in unselected patients with venous thrombosis[20]. Most 
of  studies have shown no difference in the prevalence of  
FVL between IBD patients and the healthy controls[20,34], 
but in IBD patients with TE, the prevalence of  FVL was 
significantly higher than in IBD patients without TE[20]. 
Additionally, the prevalence of  FVL in IBD patients with 
TE is comparable to its prevalence in non-IBD patients 
with TE[58,60]. Although somewhat conflicting, these ge-
netic studies suggest that FVL as a risk factor for TE in 
IBD patients matches that of  the general population. 
The G20210A gene mutation is the second most 
frequent genetic prothrombic mutation after FVL. The 
prevalence of  G20210A mutation is about 2% in healthy 
controls and 6.2% in patients with thrombosis[60]. Howev-
er, several studies have demonstrated the same prevalence 
of  the gene mutation in IBD patients with and without 
TE[60,61]. Some investigators have shown a close associa-
tion between IBD and the presence of  the G20210A 
mutation[56,57].
Methylenetetrahydrofolate reductase (MTHFR) is a 
critical enzyme involved in the remethylation pathway of  
homocysteine metabolism. A common mutation (C677T) 
has been identified in the MTHFR gene. The homozy-
gous carries of  this polymorphism are found in around 
10% of  the population and the polymorphism may be a 
cause of  moderate hyperhomocysteinemia. Some studies 
have demonstrated a weak association between C6777T 
homozygosity in the population and the risk of  thrombo-
sis[62]. However, the study that associated the prevalence 
of  C677T homozygosity between IBD thrombotic and 
IBD non-thrombotic subjects has shown no significant 
differences[58,60].
The FXIII gene mutation (val34leu) is associated with 
a higher FXIII activation rate and leads to a 20%-40% 
risk reduction of  venous thrombosis for homozygous 
carries, which are found in around 10% of  the popula-
tion[63]. The FXIII mutation has been evaluated in IBD 
patients, but the available studies have not demonstrated 
any significant differences in the prevalence of  this poly-
morphism in IBD patients with respect to the general 
population[58,64].
PAI-1 gene mutation - the 4G/4G genotype - is asso-
ciated with an overexpression of  PAI-1, which may cause 
a decreased fibrinolysis. The 4G/4G genotype has been 
demonstrated to be a risk factor in myocardial infarction, 
arterial thrombosis and DVT[20,65]. The available studies 
have demonstrated a higher prevalence of  the genotype 
in IBD patients as compared to the general population[65]. 
Investigations performed in IBD patients also assess 
other genetic hypercoagulability factors, such as deficien-
cy of  PC and PS, and ATⅢ mutation[20].
Finally, in spite of  numerous genetic studies per-
formed in IBD, no unambiguous association has been 
demonstrated between genetic factors and causes of  hy-
percoagulability in both CD and UC[20,34].
Medications
Some medications used in the treatment of  IBD patients 
may affect haemostatic system. 5-ASA used in a combi-
nation with oral anticoagulants might increase the risk of  
bleeding. Carty et al[66] observed that 5-ASA given orally 
or in vitro inhibits platelet activation.
It has been confirmed by many studies that glucocor-
ticoids increase the risk of  VTE[67]. Johannesdottir et al[67] 
in a population-based case-controlled study observed a 
higher risk of  VTE among present, new, continuing and 
recent glucocorticoids users but not among former ones. 
Glucocorticoids also inhibit oral anticoagulants.
Data regarding coagulation and use of  anti TNF 
antagonists are conflicting. For instance, in a national 
prospective observational cohort study in Great Britain 
use of  anti-TNF therapy was not associated with an in-
creased risk of  VTE in rheumatoid arthritis patients[68]. 
However, the majority of  publications confirm such a 
relationship[69]. TEs have been noted in about 4.5% of  
patients treated with TNF antagonists. One of  the pos-
sible explanations includes involvement of  anti-drug 
antibodies that might be found in some patients. It has 
been speculated that antigen-Ab complexes could trigger 
thrombosis by activating either platelets or the comple-
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ment system[69]. Another hypothesis is based on predispo-
sition of  some patients to lupus-like reactions, including 
antiphospholipid syndrome[69]. The inhibition of  TNF 
leads to overproduction of  interferon-α what might fa-
cilitate the development of  lupus-like syndrome.
Concomitant use of  thiopurines and anticoagulants 
may foster decrease in the effect of  warfarin, what might 
be caused by reduced bioavailability, enhanced warfarin 
metabolism, or increased prothrombin activity[70].
A meta-analysis of  eight randomized-controlled trials 
performed in 2007 demonstrated that administration of  
heparin in patients with UC is safe, but does not give any 
benefit over conventional therapy[71]. In 2010, a review of  
randomized trials confirmed no benefit of  low molecular 
weight heparins (LMWH) administered subcutaneously 
over placebo for clinical remission induction in patients 
with UC. However, high dose LMWH administered via 
an extended colon-release tablet showed benefit over pla-
cebo for clinical remission and endoscopic improvement. 
There is no evidence to support the use of  unfraction-
ated heparin for the treatment of  active UC[72].
Thromboprophylaxis
There are no unambiguous indications to use thrombo-
prophylaxis in patients with IBD[73]. Many national guide-
lines support their use in this patient population[74]. Euro-
pean Crohn’s and Colitis Organisation (ECCO) suggests 
to consider prevention with both mechanical thrombo-
prophylaxis and heparin in patients with UC at risk of  
TE and antithrombotic prophylaxis in all hospitalized 
patients with CD, especially in the event of  prolonged 
immobilization[75-78]. Evidence from randomized trials 
confirms that use of  heparin and LMWH is generally 
safe in patients with IBD[74]. Patients with IBD should be 
also informed about thrombotic risk factors such as oral 
contraceptive use and long-distance travel[77,78].
CONClUsION
Despite numerous studies, to date, the pathogenesis of  
IBD has not been unambiguously determined. The most 
commonly listed factors include genetic and immune 
abnormalities, although recently, discussions focus on the 
role of  endothelial damage and coagulation disturbances 
as IBD-triggering factors. Persistent hypercoagulation 
may influence the clinical course of  IBD and most likely 
is related to the interaction between chronic inflam-
matory process and coagulation cascade[34]. Activation 
of  coagulation acts as an element of  the inflammatory 
response by directly mediating cytokine responses. Also 
hypofibrinolysis seems to be a typical feature of  inflam-
mation[34]. That is why, the majority of  TEs occur during 
the active phase of  IBD[77,78]. Acquired prothrombotic 
factors also play a crucial role in development of  TE in 
IBD patients.
Further studies are necessary to assess the role of  co-
agulation abnormalities in IBD etiology and to determine 
indications for thromboprophylactic treatment in patients 
at high risk of  developing TE.
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